X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (798) 798
lopinavir/ritonavir (677) 677
hiv infections - drug therapy (658) 658
index medicus (619) 619
infectious diseases (616) 616
female (525) 525
male (521) 521
adult (483) 483
hiv (400) 400
pharmacology & pharmacy (387) 387
lopinavir (343) 343
antiretroviral therapy (338) 338
middle aged (326) 326
immunology (304) 304
ritonavir (287) 287
protease inhibitors (258) 258
ritonavir - therapeutic use (237) 237
anti-hiv agents - therapeutic use (236) 236
hiv infections - virology (234) 234
hiv protease inhibitors - therapeutic use (229) 229
virology (214) 214
microbiology (212) 212
treatment outcome (211) 211
viral load (209) 209
drug therapy, combination (200) 200
pharmacokinetics (194) 194
ritonavir - administration & dosage (194) 194
efficacy (172) 172
anti-hiv agents - administration & dosage (166) 166
safety (166) 166
hiv-1 - drug effects (157) 157
lopinavir-ritonavir (155) 155
therapy (151) 151
cd4 lymphocyte count (149) 149
hiv protease inhibitors - administration & dosage (148) 148
antiviral agents (147) 147
drug therapy (146) 146
hiv infection (146) 146
ritonavir - adverse effects (135) 135
aids/hiv (134) 134
efavirenz (130) 130
combination (127) 127
anti-hiv agents - adverse effects (126) 126
tenofovir (126) 126
human immunodeficiency virus--hiv (124) 124
hiv-1-infected patients (123) 123
hiv-1 (121) 121
aids (120) 120
hiv protease inhibitors - adverse effects (120) 120
highly active antiretroviral therapy (116) 116
protease inhibitor (115) 115
atazanavir (114) 114
hiv-infected patients (114) 114
adolescent (113) 113
antiretroviral drugs (111) 111
pyrimidinones - therapeutic use (111) 111
drug administration schedule (110) 110
atazanavir sulfate (109) 109
ritonavir - pharmacokinetics (108) 108
antiretroviral therapy, highly active (106) 106
young adult (106) 106
drug interactions (105) 105
active antiretroviral therapy (103) 103
twice-daily lopinavir/ritonavir (102) 102
hiv protease inhibitors - pharmacokinetics (96) 96
dosage and administration (95) 95
health aspects (94) 94
naive hiv-1-infected patients (94) 94
anti-hiv agents - pharmacokinetics (93) 93
research (93) 93
pyrimidinones - administration & dosage (91) 91
darunavir (90) 90
rna, viral - blood (90) 90
antiretroviral therapy, highly active - methods (88) 88
article (87) 87
aged (86) 86
reverse-transcriptase inhibitors (86) 86
drug resistance, viral (85) 85
hiv-1 - genetics (85) 85
lamivudine (83) 83
hiv infections - complications (80) 80
human-immunodeficiency-virus (80) 80
virus diseases (79) 79
prospective studies (78) 78
resistance (78) 78
clinical trials (76) 76
cohort studies (76) 76
infected patients (76) 76
analysis (74) 74
hiv infections - immunology (74) 74
retrospective studies (74) 74
hiv infections - blood (73) 73
once-daily atazanavir/ritonavir (73) 73
infection (70) 70
child (69) 69
drug combinations (66) 66
lopinavir - therapeutic use (66) 66
care and treatment (65) 65
children (65) 65
adenine - analogs & derivatives (64) 64
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1029) 1029
Spanish (36) 36
French (8) 8
Japanese (5) 5
Russian (5) 5
German (4) 4
Chinese (1) 1
Italian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


LANCET INFECTIOUS DISEASES, ISSN 1473-3099, 07/2014, Volume 14, Issue 7, pp. 572 - 580
Background Daily oral triple therapy is effective at halting HIV disease progression, but can have toxic effects and is costly. We investigated whether dual... 
INFECTIOUS DISEASES | RALTEGRAVIR | EFFICACY | SAFETY | ANALOGS | EFAVIRENZ | LOPINAVIR/RITONAVIR | DARUNAVIR/RITONAVIR | DOLUTEGRAVIR | SPARING REGIMEN | TENOFOVIR/EMTRICITABINE
Journal Article
IDCases, ISSN 2214-2509, 11/2019, p. e00643
Journal Article
AIDS, ISSN 0269-9370, 2015, Volume 29, Issue 18, pp. 2447 - 2457
Objective: To evaluate whether once daily (q.d.) lopinavir/ritonavir is noninferior to twice daily (b.i.d.) dosing in children. Design: International,... 
HIV-1 | Randomized | Trial | Children | Lopinavir/ritonavir | Once daily
Journal Article
AIDS, ISSN 0269-9370, 11/2011, Volume 25, Issue 17, pp. 2113 - 2122
Objective: To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients. Design: Phase IIb, single-arm,... 
INFECTIOUS DISEASES | SAFETY | antiretroviral therapy | nucleoside sparing | raltegravir | INITIAL TREATMENT | IMMUNOLOGY | COMBINATION | VIROLOGY | HIV-1 VIRAL LOAD | ANTIRETROVIRAL DRUG-RESISTANCE | darunavir | LOPINAVIR/RITONAVIR | INFECTION | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR
Journal Article
Drug Discovery Today, ISSN 1359-6446, 01/2019, Volume 24, Issue 1, pp. 263 - 271
Malaria is threatening a resurgence because of drug resistance against frontline artemisinin-based combination therapies (ACTs). This necessitates the... 
EARLY-PREGNANCY | SAFETY | MATERNAL USE | RESISTANCE | PROTON PUMP INHIBITORS | RISK | PHARMACOLOGY & PHARMACY | 1ST TRIMESTER | LOPINAVIR/RITONAVIR | AZITHROMYCIN | EXPOSURE
Journal Article
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 07/2019, Volume 74, Issue 7, pp. 1992 - 2002
Abstract Background Rilpivirine is widely prescribed in people living with HIV. Although trough plasma concentrations have been associated with virological... 
INFECTIOUS DISEASES | EFFICACY | SAFETY | REVERSE-TRANSCRIPTASE | ADULTS | MICROBIOLOGY | COMPARTMENTS | PHASE-3 | HIV DYNAMICS | PHARMACOKINETICS | EFAVIRENZ | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR
Journal Article
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, ISSN 0305-7453, 08/2018, Volume 73, Issue 8, pp. 2120 - 2128
Background: In the ANRS 165 DARULIGHT study (NCT02384967) carried out in HIV-infected patients, the use of a darunavir/ritonavir-containing regimen with a... 
TRIAL | INFECTIOUS DISEASES | DARUNAVIR | TREATMENT-NAIVE | PLASMA | EFFICACY | SAFETY | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | TENOFOVIR | RITONAVIR
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Journal Article
by Gianotti, N and Lorenzini, P and Cozzi-Lepri, A and De Luca, A and Madeddu, G and Sighinolfi, L and Pinnetti, C and Santoro, C and Meraviglia, P and Mussini, C and Antinori, A and Monforte, AD and Andreoni, M and Angarano, G and Castelli, F and Cauda, R and Di Perri, G and Galli, M and Iardino, R and Ippolito, G and Lazzarin, A and Perno, CF and von Schloesser, F and Viale, P and Castagna, A and Ceccherini-Silberstein, F and Girardi, E and Lo Caputo, S and Puoti, M and Ammassari, A and Balotta, C and Bandera, A and Bonfanti, P and Bonora, S and Borderi, M and Calcagno, A and Calza, L and Capobianchi, MR and Cingolani, A and Cinque, P and Di Biagio, A and Gori, A and Guaraldi, G and Lapadula, G and Lichtner, M and Maggiolo, F and Marchetti, G and Marcotullio, S and Monno, L and Nozza, S and Roldan, EQ and Rossotti, R and Rusconi, S and Santoro, MM and Saracino, A and Zaccarelli, M and Fanti, I and Galli, L and Rodano, A and Shanyinde, M and Tavelli, A and Carletti, F and Carrara, S and Di Caro, A and Graziano, S and Petrone, F and Prota, G and Quartu, S and Truffa, S and Giacometti, A and Costantini, A and Valeriani, C and Suardi, C and Donati, V and Verucchi, G and Minardi, C and Quirino, T and Abeli, C and Manconi, PE and Piano, P and Cacopardo, B and Celesia, B and Vecchiet, J and Falasca, K and Segala, D and Mazzotta, F and Vichi, F and Cassola, G and Viscoli, C and Alessandrini, A and Bobbio, N and Mazzarello, G and Mastroianni, C and Belvisi, V and Caramma, I and Chiodera, A and Castelli, AP and Rizzardini, G and Ridolfo, AL and Piolini, R and ... and ICONA Fdn Study Grp
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, ISSN 0305-7453, 09/2019, Volume 74, Issue 9, pp. 2732 - 2741
Objectives: Our aim was to investigate the durability of different initial regimens in patients starting ART with CD4+ counts <200 cells/mm(3) and HIV-RNA >5... 
INFECTIOUS DISEASES | EFFICACY | RALTEGRAVIR | ADULTS | MICROBIOLOGY | DOLUTEGRAVIR | DRUG-RESISTANCE | INDIVIDUALS | TENOFOVIR-EMTRICITABINE | NAIVE PATIENTS | PHARMACOLOGY & PHARMACY | LOPINAVIR/RITONAVIR | INHIBITOR
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 04/2011, Volume 154, Issue 7, p. 445
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1726 - 1737
In this randomized, controlled trial in Africa and India, combination antiretroviral therapy was more effective than standard therapy in preventing... 
PRETERM DELIVERY | CHILD-MORTALITY | MEDICINE, GENERAL & INTERNAL | TENOFOVIR DISOPROXIL FUMARATE | INFECTED WOMEN | PROGESTERONE LEVELS | ADVERSE BIRTH OUTCOMES | LOPINAVIR/RITONAVIR | LOPINAVIR EXPOSURE | PROTEASE | PREGNANCY | HIV Infections - prevention & control | Infant Mortality | Humans | African Americans | Perinatal Care | Infant | Young Adult | Adult | Female | HIV Infections - transmission | Drug Therapy, Combination | Infant, Newborn | Infant, Low Birth Weight | Anti-Retroviral Agents - therapeutic use | Tenofovir - therapeutic use | Zidovudine - adverse effects | Anti-Retroviral Agents - adverse effects | CD4 Lymphocyte Count | Gestational Age | Pregnancy | Infant, Premature | Zidovudine - therapeutic use | HIV Infections - ethnology | Nevirapine - administration & dosage | Infectious Disease Transmission, Vertical - prevention & control | Pregnancy Outcome | Prevention | Highly active antiretroviral therapy | Complications and side effects | Care and treatment | Nevirapine | Pregnant women | HIV patients | Dosage and administration | Research | HIV (Viruses) | Zidovudine | Health aspects | Emtricitabine | Neonates | Antiretroviral drugs | Breastfeeding & lactation | Ritonavir | Lopinavir | Lamivudine | Infants | Gestation | Antiretroviral therapy | Postpartum | CD4 antigen | Disease prevention | Tenofovir | Cost-benefit analysis | Disease transmission | Maternal & child health | Human immunodeficiency virus--HIV | Birth weight | Drug therapy
Journal Article